{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:19:29Z","timestamp":1763036369412,"version":"3.44.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"5-6","license":[{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1016\/j.pharma.2008.09.003","type":"journal-article","created":{"date-parts":[[2008,11,9]],"date-time":"2008-11-09T04:12:15Z","timestamp":1226203935000},"page":"300-308","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Apport de la radio-immunoth\u00e9rapie au traitement des lymphomes"],"prefix":"10.1016","volume":"66","author":[{"given":"N.","family":"Rizzo-Padoin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2008.09.003_bib1","first-page":"694","article-title":"Targeted therapy of cancer with radiolabeled antibodies","volume":"43","author":"Goldenberg","year":"2002","journal-title":"J Nucl Med"},{"key":"10.1016\/j.pharma.2008.09.003_bib2","first-page":"813","article-title":"Le radio-immunociblage: aspects diagnostiques et th\u00e9rapeutiques","volume":"87","author":"Vuillez","year":"2000","journal-title":"Bull Cancer"},{"key":"10.1016\/j.pharma.2008.09.003_bib3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0037-1963(00)90054-4","article-title":"Physics for practitioners \u2013 the use of radiolabeled monoclonal antibodies in B-cell non-Hodgkin's lymphoma","volume":"37","author":"Press","year":"2000","journal-title":"Semin Hematol"},{"key":"10.1016\/j.pharma.2008.09.003_bib4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00001622-199909000-00009","article-title":"Radioimmunotherapy for lymphoma","volume":"11","author":"Zelenetz","year":"1999","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.pharma.2008.09.003_bib5","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1007\/s002800100312","article-title":"Radioimmunotherapy for patients with relapsed B-cell non-hodgkin lymphoma","volume":"48","author":"Witzig","year":"2001","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.pharma.2008.09.003_bib6","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2174\/1389201013378545","article-title":"Zevalin \u2013 90yttrium labelled anti-CD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin's lymphoma","volume":"2","author":"Krasner","year":"2001","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1016\/j.pharma.2008.09.003_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/j.seminoncol.2003.10.002","article-title":"History of antibody therapy for non-Hodgkin's lymphoma","volume":"30","author":"Forero","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1016\/j.pharma.2008.09.003_bib8","first-page":"185","article-title":"Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-cell non-hodgkin's lymphoma","volume":"20","author":"Wiseman","year":"2005","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.pharma.2008.09.003_bib9","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular Non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pharma.2008.09.003_bib10","first-page":"177","article-title":"Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs","volume":"12","author":"Demidem","year":"1997","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.pharma.2008.09.003_bib11","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.semnuclmed.2003.11.002","article-title":"Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin)","volume":"34","author":"Borghael","year":"2004","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.pharma.2008.09.003_bib12","first-page":"1017","article-title":"Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma","volume":"15","author":"Chinn","year":"1999","journal-title":"Int J Oncol"},{"key":"10.1016\/j.pharma.2008.09.003_bib13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1053\/sonc.2002.30148","article-title":"Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma","volume":"29","author":"Gordon","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1016\/j.pharma.2008.09.003_bib14","first-page":"108","article-title":"Anti-CD20 monoclonal antibody therapy for non-Hodgkin's lymphoma","volume":"10","author":"White","year":"1998","journal-title":"Minerva Biotechnol"},{"key":"10.1016\/j.pharma.2008.09.003_bib15","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/j.semnuclmed.2003.11.004","article-title":"Imaging and dosing in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin)","volume":"34","author":"Spies","year":"2004","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.pharma.2008.09.003_bib16","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1040-8428(01)00107-X","article-title":"Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma","volume":"39","author":"Wiseman","year":"2001","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.pharma.2008.09.003_bib17","first-page":"3281s","article-title":"Radioimmunotherapy of relapsed Non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody","volume":"5","author":"Wiseman","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharma.2008.09.003_bib18","first-page":"253","article-title":"Additional radiation absorbed dose estimates for Zevalin radioimmunotherapy","volume":"18","author":"Wiseman","year":"2003","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.pharma.2008.09.003_bib19","first-page":"165","article-title":"Radiation dosimetry results from a phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia","volume":"18","author":"Wiseman","year":"2003","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.pharma.2008.09.003_bib20","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory, low-grade, follicular, or transformed B-cell Non-Hodgkin's Lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pharma.2008.09.003_bib21","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1200\/JCO.2003.08.043","article-title":"Safety of Yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's Lymphoma","volume":"21","author":"Witzig","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pharma.2008.09.003_bib22","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1053\/j.semnuclmed.2003.11.005","article-title":"Radiation safety considerations with yttrium 90 ibritumomab tiuxetan (zevalin)","volume":"34","author":"Zhu","year":"2004","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.pharma.2008.09.003_bib23","first-page":"267","article-title":"Administration guidelines for radioimmunotherapy of non-hodgkin's lymphoma with 90Y-labeled anti-CD20 monoclonal antibody","volume":"43","author":"Wagner","year":"2002","journal-title":"J Nucl Med"},{"key":"10.1016\/j.pharma.2008.09.003_bib24","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1007\/s00259-007-0372-y","article-title":"Therapy Committee, EANM; Oncology Committee, EANM; Dosimetry Committee, EANM. EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin)","volume":"34","author":"Tennvall","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.pharma.2008.09.003_bib25","first-page":"37","article-title":"Utilisation de l\u2019ibritumomab tiux\u00e9tan marqu\u00e9 \u00e0 l\u2019yttrium-90 dans le traitement des lymphomes non hodgkiniens \u00e0 cellules B","volume":"7","author":"Bourrel","year":"2006","journal-title":"Actual Pharm Hospitalieres"},{"key":"10.1016\/j.pharma.2008.09.003_bib26","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1097\/MNM.0b013e3282f1ac59","article-title":"Evaluation of different beta-counting systems involved in 90Y-Zevalin quality control","volume":"28","author":"Urbano","year":"2007","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.pharma.2008.09.003_bib27","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.643.643","article-title":"90Y-ibritumomab tiuxetan (Zevalin) consolidation of first remission in advanced stage follicular non-Hodgkin's lymphoma: first results of the international randomized phase 3 First-line Indolent Trial (FIT) in 414 patients","volume":"110","author":"Hagenbeek","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.pharma.2008.09.003_bib28","first-page":"S1","volume":"32","author":"Gonzalez","year":"2008","journal-title":"Med Nucl"},{"key":"10.1016\/j.pharma.2008.09.003_bib29","first-page":"478","article-title":"Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia","volume":"19","author":"Schilder","year":"2004","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.pharma.2008.09.003_bib30","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1182\/blood-2003-11-3883","article-title":"Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1\/2 study","volume":"103","author":"Gordon","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.pharma.2008.09.003_bib31","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1182\/blood-2005-03-1310","article-title":"A phase 1\/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma","volume":"106","author":"Nademanee","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.pharma.2008.09.003_bib32","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1200\/JCO.2002.02.126","article-title":"Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma","volume":"20","author":"Dillman","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pharma.2008.09.003_bib33","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1080\/10428190701528517","article-title":"Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma","volume":"48","author":"Shah","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.pharma.2008.09.003_bib34","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","article-title":"131I-tositumomab therapy as initial treatment for follicular lymphoma","volume":"352","author":"Kaminski","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharma.2008.09.003_bib35","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1182\/blood-2003-01-0287","article-title":"A phase 2 trial of CHOP chemotherapy followed by tositumomab\/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911","volume":"102","author":"Press","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.pharma.2008.09.003_bib36","first-page":"139","article-title":"La radioimmunoth\u00e9rapie des cancers","volume":"24","author":"Lev\u00eaque","year":"2005","journal-title":"J Pharm Clin"},{"key":"10.1016\/j.pharma.2008.09.003_bib37","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1038\/sj.onc.1210378","article-title":"Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab","volume":"26","author":"Davies","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.pharma.2008.09.003_bib38","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3960\/jslrt.47.43","article-title":"Radioimmunotherapy for non-hodgkin lymphoma: historical perspective and current status","volume":"47","author":"Emmanouilides","year":"2007","journal-title":"J Clin Exp Hematopathol"},{"key":"10.1016\/j.pharma.2008.09.003_bib39","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0360-3016(01)01585-1","article-title":"Advancements in cancer therapy with alpha-emitters: a review","volume":"51","author":"Imam","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.pharma.2008.09.003_bib40","first-page":"S115","article-title":"Perspectives on cancer therapy with radiolabeled monoclonal antibodies","volume":"46","author":"Sharkey","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1016\/j.pharma.2008.09.003_bib41","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1038\/sj.onc.1210373","article-title":"Novel radiolabeled antibody conjugates","volume":"26","author":"Goldenberg","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.pharma.2008.09.003_bib42","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.nucmedbio.2006.03.004","article-title":"In vitro and in vivo evaluation of novel ligands for radioimmunotherapy","volume":"33","author":"Chong","year":"2006","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.pharma.2008.09.003_bib43","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1200\/JCO.2003.01.082","article-title":"Phase I\/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma","volume":"21","author":"Leonard","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pharma.2008.09.003_bib44","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.1158\/1078-0432.CCR-04-0294","article-title":"Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I\/II clinical trial results","volume":"10","author":"Leonard","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharma.2008.09.003_bib45","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2006.05.6291","article-title":"Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma","volume":"24","author":"Strauss","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pharma.2008.09.003_bib46","first-page":"3995S","article-title":"Final results of a phase I radioimmunotherapy trial using (186)Re-epratuzumab for the treatment of patients with non-Hodgkin's lymphoma","volume":"9","author":"Postema","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharma.2008.09.003_bib47","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/10428190009060322","article-title":"Phase I\/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma","volume":"38","author":"Vose","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.pharma.2008.09.003_bib48","first-page":"3647","article-title":"A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma","volume":"20","author":"O\u2019Donnell","year":"2000","journal-title":"Anticancer Res"},{"key":"10.1016\/j.pharma.2008.09.003_bib49","first-page":"2014","article-title":"A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma","volume":"40","author":"O\u2019Donnell","year":"1999","journal-title":"J Nucl Med"},{"key":"10.1016\/j.pharma.2008.09.003_bib50","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/cbr.1993.8.3","article-title":"A phase I escalating-dose safety, dosimetry and efficacy study of radiolabeled monoclonal antibody LYM-1","volume":"8","author":"Kuzel","year":"1993","journal-title":"Cancer Biother"},{"key":"10.1016\/j.pharma.2008.09.003_bib51","unstructured":"Bruel D. M\u00e9dicaments radiopharmaceutiques et radioimmunoth\u00e9rapie\u00a0: r\u00f4le potentiel des liposomes radiomarqu\u00e9s dans l\u2019optimisation du ciblage [th\u00e8se]. Paris: universit\u00e9 de Paris V; 2002. p. 1\u2013103."},{"key":"10.1016\/j.pharma.2008.09.003_bib52","doi-asserted-by":"crossref","first-page":"5921","DOI":"10.1158\/0008-5472.CAN-07-0080","article-title":"Evaluation of CD20, CD22, and HLA-DR targetin g for radioimmunotherapy of B-cell lymphomas","volume":"67","author":"Pagel","year":"2007","journal-title":"Cancer Res"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450908001259?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450908001259?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:26:40Z","timestamp":1757719600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450908001259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":52,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["S0003450908001259"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2008.09.003","relation":{},"ISSN":["0003-4509"],"issn-type":[{"type":"print","value":"0003-4509"}],"subject":[],"published":{"date-parts":[[2008,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apport de la radio-immunoth\u00e9rapie au traitement des lymphomes","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2008.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}